JAMA October 2026 Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease The NOPARK Randomized Clinical Trial

This Week In Medicine · Oct 9, 2026 · 1m

A recent phase 3 clinical trial investigated whether the supplement nicotinamide riboside could slow the progression of early-stage Parkinson disease. Researchers across eleven centers in Norway administered either the substance or a placebo to 393 participants over a 52-week period. To measure disease severity, the study tracked changes using standard movement and non-motor symptom scales. Ultimately, the findings revealed that patients taking the supplement experienced worse clinical outcomes compared to those receiving the inactive treatment. Consequently, experts concluded that this…